David Walter Pignolet
Vorstandsvorsitzender bei Juno Therapeutics GmbH
Profil
David Walter Pignolet is currently the Co-Managing Director at Celgene SRL (Belgium) since 2017, and also holds the position of Co-Managing Director at Juno Therapeutics GmbH and Director at Celgene Ltd.
He previously worked as Co-Managing Director at Celgene SAS.
Aktive Positionen von David Walter Pignolet
Unternehmen | Position | Beginn |
---|---|---|
Juno Therapeutics GmbH
Juno Therapeutics GmbH BiotechnologyHealth Technology Part of Bristol Myers Squibb Co., Juno Therapeutics GmbH is a German company that researches and develops cellular therapies. The company is based in Munich, Germany. The CEOs of the company are David Walter Pignolet, Lothar Germeroth. Juno Therapeutics was acquired by Juno Therapeutics, Inc., part of Bristol Myers Squibb Co. from March 07, 2018 on May 11, 2015 for $232.80 million. | Vorstandsvorsitzender | - |
Celgene Ltd.
Celgene Ltd. Pharmaceuticals: MajorHealth Technology Celgene Ltd. engages in the development of human pharmaceuticals and agrochemicals. It focuses on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions. The company was founded on June 2, 2015 and is headquartered in Uxbridge, the United Kingdom. | Direktor/Vorstandsmitglied | 20.02.2019 |
Celgene SRL (Belgium)
Celgene SRL (Belgium) Miscellaneous Commercial ServicesCommercial Services Part of Bristol Myers Squibb Co., Celgene SRL (Belgium) is a Belgian company that engages in research and development on biotechnology. The company is based in Watermaal-Bosvoorde, Belgium. The CEOs are Katherine Reynolds Kelly, David Walter Pignolet. The company was founded in 2006. | Vorstandsvorsitzender | 19.09.2017 |
Ehemalige bekannte Positionen von David Walter Pignolet
Unternehmen | Position | Ende |
---|---|---|
Celgene SAS
Celgene SAS Pharmaceuticals: MajorHealth Technology Celgene SAS wholesales pharmaceutical products. Its products include Revlimid, vidaza, thalidomide, imnovid, Abraxane and Otezla. The company was founded in 1984 and is headquartered in Paris La Défense, France. | Vorstandsvorsitzender | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 4 |
---|---|
Celgene SRL (Belgium)
Celgene SRL (Belgium) Miscellaneous Commercial ServicesCommercial Services Part of Bristol Myers Squibb Co., Celgene SRL (Belgium) is a Belgian company that engages in research and development on biotechnology. The company is based in Watermaal-Bosvoorde, Belgium. The CEOs are Katherine Reynolds Kelly, David Walter Pignolet. The company was founded in 2006. | Commercial Services |
Juno Therapeutics GmbH
Juno Therapeutics GmbH BiotechnologyHealth Technology Part of Bristol Myers Squibb Co., Juno Therapeutics GmbH is a German company that researches and develops cellular therapies. The company is based in Munich, Germany. The CEOs of the company are David Walter Pignolet, Lothar Germeroth. Juno Therapeutics was acquired by Juno Therapeutics, Inc., part of Bristol Myers Squibb Co. from March 07, 2018 on May 11, 2015 for $232.80 million. | Health Technology |
Celgene Ltd.
Celgene Ltd. Pharmaceuticals: MajorHealth Technology Celgene Ltd. engages in the development of human pharmaceuticals and agrochemicals. It focuses on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions. The company was founded on June 2, 2015 and is headquartered in Uxbridge, the United Kingdom. | Health Technology |
Celgene SAS
Celgene SAS Pharmaceuticals: MajorHealth Technology Celgene SAS wholesales pharmaceutical products. Its products include Revlimid, vidaza, thalidomide, imnovid, Abraxane and Otezla. The company was founded in 1984 and is headquartered in Paris La Défense, France. | Health Technology |